Autoimmune disease has been a therapeutic backwater. No longer. A collection of innovative therapies is now coming onstream. Anne Harding covers therapies targeted at T-cell mechanisms (Click here), and Pamela Gannon explores compounds aimed at B-cell and interleukin-6 pathways and receptors (Click here). Also included is a look back over the history of approaches to battling autoimmunity.

Andrew M. Chan of Genentech brings today's pharmaceutical perspective on current and future therapeutic prospects.

And Noel R. Rose of Johns Hopkins University, doyen of autoimmunity researchers, describes the journey that led him into a career of studying autoimmunity and his hopes and expectations.

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Join for free todayAlready a member?Login Here